The review paper, Regorafenib for the Treatment of Sarcoma, was recently published in Current Treatment Options in Oncology, 23 (11):1477-1502 (2022).

We are pleased to share a snapshot of the paper in this video from Prof. Robert Maki, along with accompanying slides and an infographic summary of the findings.

Physicians face challenges in selecting the most appropriate and effective treatments for sarcomas. In this paper, experts summarise the unmet needs of this patient group and review the current trial data to examine the safety profile and clinical activity of regorafenib in sarcoma subtypes.

 

Clinical takeaways:

  • Regorafenib demonstrated benefit in patients with osteosarcoma, Ewing sarcoma and non-adipocytic soft tissue sarcomas who had progressed on prior therapy
  • Patients who have otherwise limited treatment options may benefit from regorafenib therapy

Dr Maki is a medical oncologist who has focused for over 20 years to understand tumors arising from connective tissues, which include sarcomas and other aggressive tumors that do not metastasize, such as desmoid tumors. These tumors represent less than 1% of all cancers that happen in adults. I work with patients with these diagnoses to find the right treatment for the 70 or more types of bone and soft tissue sarcomas and other soft tissue tumors. As part of this work, I also reserach new medications for cancer in general, a field called developmental therapeutics. In my research, I seek to find new medications that may be useful for sarcoma patients, and try to figure out why they work or not. I work closely with colleagues at Penn Medicine, the Children's Hospital of Philadelphia, and with other national and international teams of researchers such as SARC, the Sarcoma Alliance for Research through Collaboration, to improve the understanding and treatment of sarcomas.

Prof. Robert Maki has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

 American Society for Clinical Oncology,  Bayer, Deciphera, Kayopharm, Peel Therapeutics and Tracon.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.